odontoprev

bradsaúde

Earnings Release

1Q26

bradesco saúde | odontoprev | Atlântica hospitais | MeuDoutor Novamed | Orizon | mediservice | CROMA ONCOLOGIA

Operational and Financial Performance

São Paulo, May 4, 2026

Bradsaúde (B3: SAUD3 BZ) announces today its consolidated results for the first quarter of 2026 (1Q26). The business and financial information of the new corporate structure, which comprises the consolidated results of health and dental plan operators, clinics, hospitals and equity Investments, is presented based on unaudited consolidated management information, stated in thousands of Brazilian reais, unless otherwise indicated, in accordance with Brazilian Corporate Law, the chart of accounts issued by the Brazilian National Regulatory Agency for Private Health Insurance and Plans (ANS) applicable to healthcare operators, and the accounting practices issued by the Brazilian Accounting Pronouncements Committee (CPC) for the other entities included in the consolidation. The information disclosed in the Quarterly Information (ITR) reflects the results of Odontoprev S.A., as filed with the Brazilian Securities Commission (CVM) and B3, and is prepared in accordance with International Financial Reporting Standards (IFRS).

Summary

Odontoprev 4
Beneficiaries 5
Key Metrics 6
Bradesco saúde 10
Beneficiaries 11
Key Metrics 12
Atlântica Hospitais e Participações 13
Bradsaúde 14
Consolidated Metrics 16
New Corporate Structure 18
Upcoming Investor Relations Events 20
Earnings Videoconference 21
Appendices 22

The most comprehensive healthcare ecosystem in Brazil, Bradsaúde was created through the consolidation of leading companies across their respective segments, combining expertise, scale, innovation and financial strength to transform the healthcare experience.

Bradsaúde brings together health and dental insurance operators, hospitals, primary care clinics, technology platforms, as well as investments in diagnostics and oncology.

The Bradsaúde ecosystem includes Bradesco Saúde, Odontoprev, Mediservice, Fleury (24.9%), Atlântica Hospitais, Meu Doutor Novamed and Orizon, in addition to strategic minority stakes in new initiatives, such as Croma Oncologia.

The ecosystem serves more than 13 million beneficiaries, with approximately 4,000 hospital beds and a broad nationwide healthcare network, operating under an open, non-verticalized model, combining efficiency, quality and access.

We are driven by innovation, operational excellence and a strong commitment to the sustainability of both the business and the healthcare system. For us, healthcare is more than a service: it is a set of interconnected solutions, designed to care for people throughout all stages of life, with responsibility, a long-term vision and a clear focus on what truly matters.

Investor Relations website: www.saud3.com.br

Contact: ri@saud3.com.br

odontoprev

Beneficiaries

We recorded 9.4 million beneficiaries as of the end of March 2026, with net additions of 141 thousand new lives in 1Q26 and 504 thousand over the last twelve months.







Key Metrics


Net Revenues and Average Ticket
R$ million
1,842
1,962
2,143
2,270
2,390
2,419
20
21
21
22
22
22
2021
2022
2023
2024
2025
APR25
MAR26
+4.9%
590
619
22
22
1Q25
1Q26
Net Revenue
Average Ticket


Loss Ratio
% Revenues
39.3
40.2
39.6
38.4
38.9
-3.1 p.p.
35.8
32.7
2021
2022
2023
2024
2025
1Q25
1Q26

Contribution Margin per segment



Contribution margin = NOR – Cost of services – Selling expenses

Since 2014, the mass-market segment, including SME and individual plans, has recorded average annual growth of 14% in contribution margin in Brazilian reais, reaching R$581 million over the last twelve months, with a margin of 59%, compared to 44% in the Corporate segment, as shown in the figure above.

Financial Revenue and Net Cash

R$ million



Net Income

R$ million



Selected Metrics

Income Statement (R$ thousand, except if specified)	1Q26	1Q25	Δ %	4Q25	Δ %	APR25-MAR26	APR24-MAR25	Δ %
Beneficiaries (thousand)	**9,405**	**8,901**	**5.7%**	**9,264**	**-**	**9,405**	**8,901**	**5.7%**
Net Adds (thousand)	**141**	**(24)**	**(694.2)%**	**132**	**7.1%**	**504**	**266**	**89.3%**
Average Ticket (R$/life/month)	**22**	**22**	**-**	**22**	**-**	**22**	**22**	**-**
Net Operating Revenues	**619,471**	**590,466**	**4.9%**	**595,306**	**4.1%**	**2,418,896**	**2,309,557**	**4.7%**
Cost of Services (ex-IBNR)	202,398	211,263	-	253,706	(20.2)%	921,419	890,638	-
Loss Ratio (%)	**32.7**	**35.8**	**(3.1 p.p.)**	**42.6**	**(9.9 p.p.)**	**38.1**	**38.6**	**(0.5 p.p.)**
Net Financial Income	**22,566**	**25,924**	**(13.0)%**	**29,356**	**(23.1)%**	**95,858**	**106,507**	**(10.0)%**
Net Income	**150,572**	**166,632**	**(9.6)%**	**108,887**	**38.3%**	**534,399**	**544,828**	**-**
Net Margin (%)	**24.3**	**28.2**	**(3.9 p.p.)**	**18.3**	**6.0 p.p.**	**22.1**	**23.6**	**(3.9 p.p.)**

Quarterly Income Statement Evolution Odontoprev **1Q25-1Q26**

Income Statement (R$ thousand, except if specified)	1Q25	2Q25	3Q25	4Q25	1Q26
Beneficiaries (thousand)	**8,901**	**8,981**	**9,132**	**9,264**	**9,405**
Net Adds (thousand)	**(24)**	**81**	**151**	**132**	**141**
Average Ticket (R$/life/month)	**22**	**23**	**22**	**22**	**22**
Net Operating Revenues	**590,466**	**601,846**	**602,274**	**595,306**	**619,471**
Cost of Services (ex-IBNR)	211,263	220,846	244,479	253,706	202,398
Loss Ratio (%)	**35.8**	**36.7**	**40.6**	**42.6**	**32.7**
Net Financial Income	25,924	19,276	24,210	29,356	22,566
Net Income	**166,632**	**146,196**	**128,744**	**108,887**	**150,572**
Net Margin (%)	**28.2**	**24.3**	**21.4**	**18.3**	**24.3**

Annual Income Statement Evolution Odontoprev **2020-2025**

Income Statement (R$ thousand, except if specified)	2020	2021	2022	2023	2024	2025
Beneficiaries (thousand)	**7,510**	**7,984**	**8,318**	**8,618**	**8,924**	**9,264**
Net Adds (thousand)	**111**	**474**	**334**	**300**	**306**	**339**
Average Ticket (R$/life/month)	**20**	**20**	**21**	**21**	**22**	**22**
Net Operating Revenues	**1,765,338**	**1,842,434**	**1,961,685**	**2,142,695**	**2,269,786**	**2,389,891**
Cost of Services (ex-IBNR)	716,820	724,314	789,345	849,303	871,436	930,284
Loss Ratio (%)	**40.6**	**39.3**	**40.2**	**39.6**	**38.4**	**38.9**
Net Financial Income	5,148	39,226	72,667	82,220	109,808	99,214
Net Income	**361,128**	**380,359**	**452,171**	**536,554**	**529,008**	**550,458**
Net Margin (%)	**20.5**	**20.6**	**23.1**	**25.0**	**23.3**	**23.0**

bradesco
saúde

Beneficiaries

We recorded 3.9 million beneficiaries as of the end of March, with net additions of 52,000 new members in 1Q26 and 206,000 over the last twelve months.

Quaterly Net Adds
Thousand Lives



Beneficiaries
Thousand Lives



Key Metrics

Written Premiums

R$ million



Net Income

R$ million



Loss Ratio

%



Atlântica

Hospitals and Investments

Atlântica

Hospitals and Investments

R$ 4.8 billion
Total committed

R$ 2.8 billion
Already deployed

Assets	Opening	# beds
Grupo Santa	**October 2024**	**1,448**
Santa Lúcia Gama (DF)	-	199
Santa Lúcia Sul (DF)	-	402
Santa Lúcia Norte (DF)	-	201
Santa Lúcia Taguatinga (DF)	-	24
Hospital Ortopédico (MT)	-	25
Hospital Santa Rosa (MT)	-	163
Ânima Centro Hospitalar (GO)	-	192
Hospital do Coração (MS)	-	72
Hospital Bauru (SP)	-	170
Atlântica D'or	**May 2024[1]**	**1,920**
Guarulhos	November 2024	268
Alphaville	November 2025	212
Macaé	November 2026	140
Campinas	April 2025	325
Glória	February 2026	337
Maternidade Star	March 2026	173
Ribeirão Preto	2Q27	138
Taubaté	1Q28	161
Sorocaba	2Q28	166
Albert Einstein	**4Q29**	**302**
Vila Mariana	-	302
Mater Dei	**4Q29**	**251**
Zona Norte	-	251
TOTAL		**3,921**

[1] *Material Fact 05.08.24*

bradsaúde

Consolidated Metrics bradsaúde

- ✓ Net income reached R$1.3 billion in 1Q26, with annualized ROAE of 24.8%
- ✓ Financial assets of R$28.6 billion
- ✓ Bradsaúde share capital of 2,924,199,731 shares

Operational Indicators	1Q26
Beneficiaries (thousand)	**13,381**
Healthcare Plans	**3,976**
Corporate	3,070
Individual	99
ASO	807
Net Adds	**52**
Dental Plans	**9,405**
Corporate	8,510
Individual	895
Net Adds	**141**
Average Ticket ex-ASO (R$/life/month)	**1,134**
Average Ticket Dental (R$/life/month)	**22**

Summary Table (R$ million)	1Q26
Revenues from Healthcare Assistance	13,278
Change in Technical Provisions for Healthcare Assistance	-88
Earned Premiums	**13,191**
Incurred Claims/Retained Claims	-10,414
Selling Expenses	-542
Financial Income	875
Income from Operations	**3,109**
Service revenues related to operations	113
Other operating expenses	-409
Tax expenses	-126
Administrative expenses	-567
Operating Income	**2,121**
Non-operating and equity income	16
Income tax, social contribution and profit sharing	-830
Net Income	**1,308**
Financial Assets	**28,573**
ROAE	**24.8**

[1]Includes revenue from Novamed and Orizon services, and revenue from goods and services (Odontoprev).

[2]Includes PIS/Cofins, federal and municipal taxes on revenue.

[3]Includes Pacífico Operações, Grupo Santa, Atlântica Imobiliária, Croma Oncologia, and a stake in Grupo Fleury.

Financial Assets and Financial Result

R$ million



Composition of Net Income 1Q26

% Net income



New Corporate Structure

On April 6, an Extraordinary Shareholders' Meeting of Odontoprev (the "Company") approved all matters related to the business combination involving the Company and Bradesco Gestão de Saúde S.A. ("BGS"), including the merger of shares issued by BGS into Odontoprev and the contribution of the dental plan portfolio and other operating assets and liabilities to Mediservice Operadora de Planos de Saúde S.A. ("Mediservice").

Authorizations from the Brazilian National Regulatory Agency for Private Health Insurance and Plans ("ANS") were obtained on March 30 for the share merger and on April 2 for the contribution of assets and liabilities.

As of the trading session on May 5 (inclusive), the Company's shares will begin to trade on B3 S.A. – Brasil, Bolsa, Balcão, under the new trading code (ticker) "**SAUD3**", and its trading name became "**BRADSAUDE**".



[1]Excludes 732,100 treasury shares from the calculation of the ownership stake;
[2]Financial investment in a private equity fund;
[3]Joint ventures to be formed between Atlântica Hospitais and Mater Dei and Einstein for the construction of the Zona Norte and Vila Mariana hospitals, respectively. Operations are scheduled to begin in 2030, at which point the joint ventures will become a joint venture controlled by the Company, which will hold a 51% stake.

History:

On February 27, 2026, a Material Fact was disclosed detailing the stages of the transaction and business combination involving Bradesco Gestão de Seguros and the Company, following approval of the steps described below:

• On December 18, 2025, as a result of an internal corporate reorganization within the Bradesco economic group, Bradesco Gestão de Saúde S.A. received, through a partial spin-off from Bradesco Saúde S.A., all of the common shares issued by Odontoprev, corresponding to 292,213,236 registered, book-entry common shares with no par value, representing 53.54% of the Company's total and voting share capital.
• On January 6, 2026, Bradseg Participações S.A. received, through a partial spin-off from Bradesco Gestão de Saúde S.A., all of the common shares issued by Odontoprev, corresponding to 292,213,236 registered, book-entry common shares with no par value, representing 53.54% of the Company's total and voting share capital.
• On March 31, Banco Bradesco S.A. received, through a partial spin-off from Bradseg Participações S.A., all of the common shares issued by Odontoprev, corresponding to 292,213,236 registered, book-entry common shares with no par value, representing 53.54% of the Company's total and voting share capital.

All Material Facts and Notices to the Market are available on our CVM Filings Page.

Upcoming Investor Relations Events

Investor Relations activities at Bradsaúde, including conferences, webcasts, one-on-one meetings and public presentations, are always conducted with the participation of the Company's Chief Executive Officer and/or Investor Relations Officer.

Date			
May 4			Earnings Release Q126
May 5			Videoconference Q126
May 5	btg pactual		Investor Presentation | São Paulo
May 6	bradesco bbi		Investor Presentation | São Paulo
May 7	btg pactual		NDR | Rio de Janeiro
May 11-12	RBC Royal Bank		NDR | Toronto and Montreal
May 13-14	Itaú BBA		19th Annual LatAm CEO Conference | New York
May 15	Santander		NDR | Florida
Mai 27-29	citi		NDR | Zurich and Genebra
Jun 1	citi		NDR | Paris
Jun 2-3	bradesco bbi		Bradesco BBI 17th Conference | London
Jun 4	UBS BB Investment Bank		NDR | Edinburgh
Jun 16	citi		18ª Brazil Equity Conference | São Paulo
Jun 22	Goldman Sachs		Investor Presentation | São Paulo
Aug 17	Santander		27ª Annual Conference | São Paulo
Aug 18	xp		CEO Conference Brazil | Rio de Janeiro
Aug 24	J.P.Morgan		Consumer and Healthcare Check Up | São Paulo

Earnings Videoconference

May 5th, 2026 – Tuesday

11h (10h NY e 15h London)

Webcast: **Clich here**

Portuguese with Simultaneous translation into English

Investor Relations

José Roberto Pacheco – IRO

Catarina Bruno – Supervisor

Maria Eduarda Rodrigues – Analyst

Corporate Communication:
imprensa@bradescoseguros.com.br

Visit our website: www.saud3.com.br

Contact us: ri@saud3.com.b

About Bradsaúde

The most comprehensive healthcare ecosystem in Brazil, Bradsaúde was created through the consolidation of leading companies across their respective segments, combining expertise, scale, innovation and financial strength to transform the healthcare experience. It serves more than 13 million beneficiaries, with approximately 4,000 hospital beds and a broad nationwide healthcare network, operating under an open, non-verticalized model, combining efficiency, quality and access.

Appendices

Appendices **23 a 28**
Appendix I – Beneficiaries Bradesco Saúde and Odontoprev 23
Appendix II - Beneficiaries Bradesco Dental and Other Brands 24
Appendix III – Odontoprev Income Statement 25
Appendix IV – Odontoprev Balance Sheet: Assets 26
Appendix V – Odontoprev Balance Sheet: Liabilities 27
Appendix VI –Odontoprev Cashflow Statement 28

Appendix I – Beneficiaries Bradesco Saúde and Odontoprev

		HEALTH				DENTAL		
	TOTAL	**Total**	Corporate	Individual	ASOs	**Total**	Corporate	Individual
2014	**10,842**	**4,526**	3,199	179	1,147	**6,316**	5,892	425
2015	**10,853**	**4,444**	3,114	171	1,158	**6,409**	5,854	555
2016	**10,379**	**4,112**	2,922	162	1,028	**6,267**	5,600	667
2017	**10,046**	**3,736**	2,676	152	909	**6,309**	5,667	642
2018	**10,855**	**3,625**	2,595	142	887	**7,230**	6,252	978
2019	**11,066**	**3,666**	2,711	134	821	**7,400**	6,372	1,027
2020	**11,169**	**3,658**	2,695	127	836	**7,510**	6,450	1,060
2021	**11,783**	**3,799**	2,854	118	827	**7,984**	6,922	1,063
2022	**12,358**	**4,040**	3,042	114	885	**8,318**	7,289	1,029
2023	**12,475**	**3,857**	2,905	108	843	**8,618**	7,659	959
2024	**12,707**	**3,783**	2,842	104	837	**8,924**	7,967	957
2025	**13,187**	**3,923**	3,040	100	784	**9,264**	8,348	916
MAR25	**12,671**	**3,770**	2,859	103	808	**8,901**	7,946	954
MAR26	**13,381**	**3,976**	3,070	99	807	**9,405**	8,510	895

Appendix II - Beneficiaries Bradesco Dental and Other Brands

	Portfolio MAR26	% segment	1Q26	2025	Portfolio MAR25	% segment	1Q25	2024
Total	**9,404,890**	**100.0%**	**141,161**	**339,460**	**8,900,512**	**100.0%**	**(23,757)**	**306,376**
bradesco dental	4,897,651	52.1%	59,961	267,392	4,560,899	51.2%	(9,399)	283,892
Others[1]	4,507,239	47.9%	81,200	72,068	4,339,613	48.8%	(14,358)	22,484
Corporate	**6,662,750**	**100.0%**	**138,166**	**165,964**	**6,299,893**	**100.0%**	**(58,727)**	**250,776**
bradesco dental	2,965,743	44.5%	36,016	77,096	2,805,306	44.5%	(47,325)	153,339
Others[1]	3,697,007	55.5%	102,150	88,868	3,494,587	55.5%	(11,402)	97,437
SME	**1,846,649**	**100.0%**	**23,585**	**214,560**	**1,646,333**	**100.0%**	**37,829**	**57,238**
bradesco dental	1,511,616	81.9%	27,665	193,389	1,325,045	80.5%	34,483	137,255
Others[1]	335,033	18.1%	(4,080)	21,171	321,288	19.5%	3,346	(80,017)
Individual Plans	**895,491**	**100.0%**	**(20,590)**	**(41,064)**	**954,286**	**100.0%**	**(2,859)**	**(1,638)**
bradesco dental	420,292	46.9%	(3,720)	(3,093)	430,548	45.1%	3,443	(6,702)
Others[1]	475,199	53.1%	(16,870)	(37,971)	523,738	54.9%	(6,302)	5,064

[1]On Corporate and SME, includes Odontoprev, Odonto System, Mogidonto and Brasildental. On Individual Plans, also includes retail channels.

Appendix III – Odontoprev Income Statement

R$000	1Q25	1Q25 ANS	1Q26	1Q26 ANS
(+) Payments net	601,302	582,548	629,672	612,855
(+) Sales of services and products	13,737	13,737	14,442	14,442
(+) Odontored (México)	7,234	7,051	8,473	8,182
Gross operating revenue	**622,273**	**603,336**	**652,587**	**635,480**
(-) Direct taxes on dental care operations	28,558	28,558	29,849	29,849
(-) Taxes on sales of services and products	3,249	3,249	3,267	3,267
Net operating revenue	**590,466**	**571,529**	**619,471**	**602,364**
(-) Cost of services	**205,633**	**186,751**	**205,987**	**189,360**
Indemnifiable claims, net	184,203	165,448	176,591	159,774
Odontored (México)	2,340	2,340	2,625	2,606
Payroll charges on services	-	-	-	91
Dental materials	4,117	3,802	3,872	3,559
Other operational costs and provisions/ reversals	20,604	20,791	19,310	19,740
Incurred but Not Reported Provision (IBNR)	(5,401)	(5,401)	3,162	3,162
Odontored - Technical reserves	(229)	(229)	427	427
Gross profit	**384,833**	**384,778**	**413,484**	**413,003**
(-) Selling expenses	**58,759**	**58,759**	**68,546**	**68,545**
(+) Other operating revenues	**774**	**957**	**342**	**4,611**
(-) General and Administrative Expenses	**94,762**	**94,890**	**121,475**	**121,575**
G&A (adjusted at EBITDA base)	**79,830**	**79,958**	**104,230**	**104,329**
Personnel	45,803	45,634	51,507	51,251
Third parties services	16,528	16,770	30,219	30,866
Rentals and post services	9,527	9,257	11,360	10,753
Publicity and advertising	3,951	3,951	5,523	5,523
Taxes and fees	1,967	1,973	1,511	1,511
Others	2,054	2,373	4,110	4,426
G&A (not adjusted at EBITDA base)	**14,932**	**14,932**	**17,245**	**17,246**
Depreciation and amortization	13,383	13,383	16,020	16,020
Amortization of utilization rights	1,549	1,549	1,225	1,225
(-) Other operating expenses	**17,616**	**17,616**	**29,153**	**32,843**
Allowance for doubtful receivables	7,155	7,155	15,053	19,027
Profit sharing	6,220	6,220	8,772	8,488
Long term incentive plan	4,241	4,241	5,328	5,328
(+) Equity in subsidiaries	**1,651**	**1,651**	**1,598**	**1,598**
Income before financial income (expenses) and taxes	**216,121**	**216,121**	**196,250**	**196,250**
(+) Net financial income	**25,924**	**25,924**	**22,566**	**22,566**
(+) Financial income	**32,251**	**32,251**	**28,850**	**28,850**
(-) Financial expenses	**6,327**	**6,327**	**6,284**	**6,284**
Income before taxes	**242,044**	**242,044**	**218,816**	**218,816**
(-) Income and social contribution tax	**75,567**	**75,567**	**68,234**	**68,233**
(-) Current income and social contribution tax	60,683	60,683	72,096	72,096
(-) Deferred income and social contribution tax	14,884	14,884	(3,862)	(3,862)
Net income before participation of minoritary shareholders	**166,477**	**166,477**	**150,583**	**150,583**
(+) Participation of minoritary shareholders	155	155	(11)	(11)
Net income	**166,632**	**166,632**	**150,572**	**150,572**

Appendix IV – Odontoprev Balance Sheet: Assets

ASSETS (R$000)	03/31/2026	12/31/2025	03/31/2025
CURRENT ASSETS	**756,230**	**536,501**	**720,891**
Cash and banks	**17,540**	**19,948**	**21,617**
Cash and cash equivalents	17,540	19,948	21,617
Cash Investments	**507,388**	**273,085**	**476,273**
Cash collateral related to technical provisions	66,942	59,344	38,264
Short-term investments	440,446	213,741	438,009
Healthcare receivables	**101,978**	**98,371**	**100,587**
Healthcare receivables	86,750	85,209	95,729
Allowance for doubtful accounts	(19,832)	(21,107)	(24,164)
Participation of beneficiaries on indemnifiable events/claims	1,595	2,189	1,379
Healthcare plan operators	9,320	5,494	8,722
Other credits from healthcare plan operations	24,145	26,586	18,921
Insurance and reinsurance contract assets	-	-	-
Notes receivable	**43,621**	**48,160**	**40,618**
Inventories	**26**	**26**	**6**
Prepaid taxes	**36,112**	**42,924**	**30,896**
Social security fiscal Credits	36,112	42,924	30,896
Prepaid expenses	**7,637**	**10,576**	**44,284**
Deferred selling expenses	-	-	38,321
Others	7,637	10,576	5,963
Other current assets	**41,928**	**43,411**	**6,610**
Non-recurrent assets for sale	41,928	43,411	6,610
NON-CURRENT ASSETS	**1,461,794**	**1,510,656**	**1,601,170**
Long-term assets	**461,014**	**514,894**	**622,758**
Long-term financial assets, held to maturity	**362,079**	**420,134**	**538,771**
Cash collateral related to technical provisions	80,351	89,981	137,942
Long-term investments	281,728	330,153	400,829
Deferred taxes	**-**	**-**	**-**
Deferred income tax & social contribution	-	-	-
Prepaid expenses	**117**	**13**	
Other non current assets	**98,818**	**94,747**	**83,987**
Non-current assets held for sale	-	6,773	
Escrow deposits	39,419	37,879	34,313
Other receivables	16,249	12,982	14,286
Tax and social security credits	43,150	37,113	35,388
Investments	**5,113**	**3,899**	**6,016**
Equity participation on affiliates	-	-	1,735
Investment in joint ventures	4,116	3,843	4,225
Other investments	997	56	56
Property and equipment	**42,694**	**44,392**	**50,354**
Intangible	**952,973**	**947,471**	**922,042**
Goodwill on acquisition of investments	676,917	669,469	669,469
System development, software licenses and other	250,284	251,979	225,797
Allocated intangible assets	25,772	26,023	26,775
TOTAL ASSETS	**2,218,024**	**2,047,157**	**2,322,061**

Appendix V – Odontoprev Balance Sheet: Liabilities

ITIES AND NET ASSETS (R$000)	31/03/2026	31/12/2025	31/03/2025
CURRENT LIABILITIES	**633,235**	**621,098**	**749,738**
Payroll charges & Labour related fees	**82,288**	**71,995**	**77,509**
Suppliers	**57,320**	**49,454**	**50,626**
Taxes payable	**51,435**	**37,573**	**34,383**
Other liabilities	**162,453**	**159,542**	**290,443**
Dividends, IOC and capital reduction	128,613	128,613	263,875
Minimum statutary dividend payable	-	-	-
Other payables	33,840	30,929	26,568
Insurance and reinsurance contract liabilities	-	-	-
Technical provisions for contingencies	**279,739**	**302,534**	**296,777**
Healthcare claims payable	55,404	55,664	66,375
IBNR reserves – Incurred but not reported claims reserves	71,741	68,579	68,988
Unearned premiums reserves	128,368	150,637	146,563
Odontored - Claims reserves and provision for losses	20,024	23,638	14,851
Tax, Social Security, Labor, and Civil Provisions	4,202	4,016	
NON-CURRENT LIABILITIES	**133,424**	**126,745**	**153,085**
Other obligations	**55,254**	**50,008**	**62,226**
Other liabilities	14,040	13,996	15,498
Fees payables	726	53	91
Investments payable	-	-	2,788
Leasing liability	13,743	14,261	18,766
Long Term Incentive Plan	-	-	24,789
Taxes and charges to be collected	226	269	294
Other accounts payable	26,519	21,429	
Deferred taxes	**16,958**	**23,328**	**12,704**
Deferred income tax and social contribution	16,958	23,328	12,704
Provisions	**61,212**	**53,409**	**78,155**
Technical provisions for contigencies	55,566	53,348	78,155
Others provisions	5,646	61	-
TOTAL LIABILITIES	**766,659**	**747,843**	**902,823**
Shareholders equity, capital and capital reserves	**1,448,981**	**1,298,883**	**1,418,929**
Capital	**851,017**	**851,017**	**851,017**
Capital reserves	**(35,610)**	**(35,610)**	**(35,610)**
Earnings reserve	**481,636**	**481,636**	**460,726**
Legal reserve	154,951	154,951	127,428
Tax incentive	129	129	129
Proposed additional dividend	-	-	81,000
Treasury shares	(7,832)	(7,832)	(79,436)
Statutory reserve for regulatory capital	100,000	100,000	100,000
Reserves for future investments and expansion	234,388	234,388	231,605
First application of reserves	-	-	-
Retained earnings	**150,572**	**-**	**141,883**
Equity valuation adjustments	**(799)**	**(792)**	**(801)**
Accumulated conversion adjustments	**2,165**	**2,632**	**1,714**
Other comprehensive results	**-**	**-**	**-**
Non controling shareholders participation	**2,384**	**431**	**309**
SHAREHOLDER´S EQUITY	**1,451,365**	**1,299,314**	**1,419,238**
LIABILITIES AND SHAREHOLDERS EQUITY	**2,218,024**	**2,047,157**	**2,322,061**

Appendix VI – Odontoprev Cashflow Statement

(R$000)	1Q25	1Q26
CASH FLOW FROM OPERATIONAL ACTIVITIES		
Net income for the period	**166,477**	**150,583**
Reconciliation of net income with the cash generated by operations		
Depreciation and amortization	14,932	17,228
Monetary variations, net	1,006	(4,499)
Provision for contingencies	953	2,002
Gain (loss) on sale of property and equipment and investments	1,053	1,710
Equity in subsidiaries	(1,650)	(1,598)
Allowance for doubtful receivables	7,155	19,027
Incurred but not reported claims reserves (IBNR)	(5,401)	3,162
Provision for income and social contribution	75,567	68,234
Unearned premiums reserve	1,781	(16,684)
IFRS 16 implementation effects	-	447
Revenues to be appropriated (CPC 47/IFRS15)	-	-
Technical claims reserves variation	(229)	427
NET CASH FROM OPERATIONAL ACTIVITIES	**166,477**	**150,583**
Decrease (increase) in operational assets	**(25,446)**	**(10,378)**
Healthcare receivables	229	(22,634)
Other receivables	(25,932)	11,580
Stock	50	-
Long-term receivables	207	676
Insurance and reinsurance contracts of assets and liabilities	-	-
Increase (decrease) in operational liabilities	**(65,832)**	**(38,221)**
Healthcare claims payable	720	(260)
Fiscal obligations (taxes payable)	(2,269)	(7,132)
Legal obligations, suppliers, and other accounts payable	(2,252)	17,713
Long-term liabilities	5,671	4,082
Income tax and social contribution paid	(70,925)	(51,023)
Social obligations	-	-
Selling expenses of operations	6,720	2,628
Odontored - Provisions for losses	(2,942)	(4,041)
Interest paid	(555)	(188)
NET CASH PROVIDED BY (USED IN) OPERATIONAL ACTIVITIES	**75,199**	**101,984**
CASH FLOW FROM INVESTING ACTIVITIES		
Acquisition of property and equipment	(444)	(1,074)
System development, software licenses and other	(14,178)	(15,602)
Deferred selling expenses	1,575	1,324
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	**(13,047)**	**(15,352)**
CASH FLOW FROM FINANCING ACTIVITIES		
Dividends paid	-	-
Interest on capital paid	(21,642)	-
Share repurchased	(10,282)	-
Rent payments	(2,137)	(2,248)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	**(34,061)**	**(2,248)**
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	**28,091**	**84,383**
Cash, Cash Equivalents and short-term investiments		
Balance at the beginning of period	913,403	713,168
Balance at the end of period	1,036,661	887,007
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	**28,091**	**84,383**